Results 41 to 50 of about 59,825 (253)

A Case of B-cell Precursor Acute Lymphoblastic Leukemia with the t(14;22)(q32;q11) Presenting Hyperleukocytosis

Clinical Pediatric Hematology-Oncology, 2022
B-cell precursor acute lymphoblastic leukemia (BCP-ALL), which is the most common type of ALL, has an excellent prognosis with long-term event-free survival of 90%.
Jianne Lee, Sun Young Kim, Yeon Jung Lim
doaj   +1 more source

Toll-like Receptors 2, 3, and 4 in Childhood Acute Lymphocytic Leukemia

Revista Brasileira de Cancerologia, 2023
Introduction: Acute lymphocytic leukemia (ALL) is the most common cancer type in children and accounts for 80% of pediatric leukemias. Novel targets are necessary to improve survival rates for refractory and relapsed disease.
Matheus Loureiro da Silva Cruz, Rafael Pereira dos Santos, Barbara Kunzler Souza, Mariane da Cunha Jaeger, Camila Alves da Silva, Lauro José Gregianin, Jiseh Fagundes Loss, Rebeca Ferreira Marques, Algemir Lunardi Brunetto, André Tesainer Brunetto, Rafael Roesler, Caroline Brunetto de Farias   +11 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

Venetoclax Drives Significant Shifts in BIM and BCL-2 but not MCL-1 Gene Expression in a Mouse Model of Acute Lymphoblastic Leukemia [PDF]

Middle East Journal of Cancer
Background: T and B acute lymphoblastic leukemia (T, B-ALL) has seen improved survival rates with intensified chemotherapy, but therapy-resistant or refractory ALL remains a significant clinical challenge.
Saeid Abroun, Kaveh Tari
doaj   +1 more source

Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims The objective of this study was to evaluate the efficacy and feasibility of the pediatric-inspired regimen of the adult acute lymphoblastic leukemia (ALL) Working Party, the Korean Society of Hematology.
Dong Won Baek, Dae Young Kim, Sang Kyun Sohn, Youngil Koh, Sung-Hoon Jung, Ho-Young Yhim, Yunsuk Choi, Joon Ho Moon   +7 more
doaj   +1 more source

Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion

Haematologica, 2019
Fusion genes involving MEF2D have recently been identified in precursor B-cell acute lymphoblastic leukemia, mutually exclusive of the common risk stratifying genetic abnormalities, although their true incidence and associated clinical characteristics ...
Kentaro Ohki, Nobutaka Kiyokawa, Yuya Saito, Shinsuke Hirabayashi, Kazuhiko Nakabayashi, Hitoshi Ichikawa, Yukihide Momozawa, Kohji Okamura, Ai Yoshimi, Hiroko Ogata-Kawata, Hiromi Sakamoto, Motohiro Kato, Keitaro Fukushima, Daisuke Hasegawa, Hiroko Fukushima, Masako Imai, Ryosuke Kajiwara, Takashi Koike, Isao Komori, Atsushi Matsui, Makiko Mori, Koichi Moriwaki, Yasushi Noguchi, Myoung-ja Park, Takahiro Ueda, Shohei Yamamoto, Koichi Matsuda, Teruhiko Yoshida, Kenji Matsumoto, Kenichiro Hata, Michiaki Kubo, Yoichi Matsubara, Hiroyuki Takahashi, Takashi Fukushima, Yasuhide Hayashi, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara, for the Tokyo Children’s Cancer Study Group (TCCSG)   +38 more
doaj   +1 more source

V_H replacement in rearranged immunoglobulin genes [PDF]

, 2005
Examples suggesting that all or part of the V_H segment of a rearranged V_HDJ_H may be replaced by all or part of another V_H have been appearing since the 1980s ...
Brokaw JL, Cascalho M, Choi Y, Chukwuocha RU, Covey LR, Cuomo CA, Deane M, Golub R, Han JO, Hesse JE, Kleinfield RW, Kobrin CB, Lewis SM, Ramsden DA, Rosenquist R, Shiokawa S, Sims GP, Steenbergen EJ, Steenbergen EJ, Taki S, Wasserman R, Wasserman R   +21 more
core   +2 more sources

Novel Markers in Pediatric Acute Lymphoid Leukemia: The Role of ADAM6 in B Cell Leukemia

Frontiers in Cell and Developmental Biology, 2021
BackgroundThe extensive genetic heterogeneity found in the B cell precursor acute lymphoblastic leukemia (BCP-ALL) subtype of childhood ALL represents a potential repository of biomarkers. To explore this potential, we have carried out in silico analysis
Laila Alsuwaidi, Mahmood Hachim, Mahmood Hachim, Abiola Senok   +3 more
doaj   +1 more source

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Biomarker Research, 2019
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical ...
Amandeep Aujla, Ravijot Aujla, Delong Liu   +2 more
doaj   +1 more source

Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

Frontiers in Immunology, 2021
T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma.
Marika Guercio, Simona Manni, Iolanda Boffa, Simona Caruso, Stefano Di Cecca, Matilde Sinibaldi, Zeinab Abbaszadeh, Antonio Camera, Roselia Ciccone, Vinicia Assunta Polito, Francesca Ferrandino, Sofia Reddel, Maria Luigia Catanoso, Emilia Bocceri, Francesca Del Bufalo, Mattia Algeri, Biagio De Angelis, Concetta Quintarelli, Concetta Quintarelli, Franco Locatelli, Franco Locatelli   +20 more
doaj   +1 more source